Media and Games Invest’s (MGI’s) recent EGM confirmed that the group can now proceed with its reloca...
Redeye provides a first comment on the back of Modelon's Q3 report.
Adj. EBIT SEK 130m (+65% vs. ABGSCe 79m) Still looking to divest Russian business 1.
Sammantaget var kvartalet positivt med ett förväntat utfall.
Redeye states that the Q3 report was more or less in line with estimates, albeit somewhat on the low...
Monivent har en pågående företrädesemission om cirka 14,8 MSEK och en riktad emission om cirka 1,6 M...
Redeye leaves its fair value range unchanged on the back of this Q3 report, which was in line with o...
Redeye updates its estimates and base case following Freemelt’s Q3 report, which came in slightly be...
Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight...
Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured so...
Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its pr...
Relais' Q3 results were in line with our expectation and above the low-quality Refinitiv consensus.
Redeye retains its positive view on Vertiseit following a solid Q3, with margins beating our forecas...
We revise our ’22e-’24e sales forecasts by 0 to +2%.
Redeye states that Q3 revenues are still not satisfactory but that it’s good that the burn rate is k...
IRLAB Therapeutics has reported Q322 results, providing an operational and financial update that are...
Redeye sees good progress in the third quarter, although we had hoped for even a little bit more.
Redeye raises its full-year 2022 forecast but maintains its previous expectations for the years afte...
Bra organisk tillväxt Organisk tillväxt var 8% i Q3 (2% i Q3'21 och 6% i Q2'22).
Q3 i korthet Under det tredje kvartalet 2022 uppvisade Physitrack en omsättning om EUR 3,4m (EUR 2,0...
